Location of LMNA Variants and Clinical Outcomes in Cardiomyopathy
https://jamanetwork.com/journals/jamacardiology/fullarticle/2845799
To the Editor The article by Bhaskaran et al, which used a large multicenter cohort of patients with pathogenic/likely pathogenic (P/LP) variants in LMNA-encoded lamin A/C to ascertain the impact of variant location on cardiac outcomes, is welcome. However, the large number of patients with familial partial lipodystrophy type 2 (FPLD2) included in this study raises concerns about the conclusion that tail-domain missense variants are associated with lower risk of major ventricular arrhythmia (VA) and heart failure (HF) events.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2845799
To the Editor The article by Bhaskaran et al, which used a large multicenter cohort of patients with pathogenic/likely pathogenic (P/LP) variants in LMNA-encoded lamin A/C to ascertain the impact of variant location on cardiac outcomes, is welcome. However, the large number of patients with familial partial lipodystrophy type 2 (FPLD2) included in this study raises concerns about the conclusion that tail-domain missense variants are associated with lower risk of major ventricular arrhythmia (VA) and heart failure (HF) events.
❤1
Location of LMNA Variants and Clinical Outcomes in Cardiomyopathy—Reply
https://jamanetwork.com/journals/jamacardiology/fullarticle/2845798
In Reply We welcome the letter by Castrichini et al highlighting their concerns about the inclusion of patients with familial lipodystrophy type 2 (FPLD2) in our recent article describing the cardiac outcomes of patients with LMNA variants. We agree that the results of prior preclinical and observational studies suggest an alternative pathomechanistic pathway for patients with p.Arg482 hotspot variants compared with other LMNA variants. Inclusion of this cohort in our study was to further interrogate these findings and appreciate the full spectrum of cardiac disease with LMNA variants. While there were no primary outcome events in this subgroup, 4 patients with missense variants affecting the p.Arg482 hotspot did experience advanced heart failure events, highlighting its relevance for overall cardiac outcomes.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2845798
In Reply We welcome the letter by Castrichini et al highlighting their concerns about the inclusion of patients with familial lipodystrophy type 2 (FPLD2) in our recent article describing the cardiac outcomes of patients with LMNA variants. We agree that the results of prior preclinical and observational studies suggest an alternative pathomechanistic pathway for patients with p.Arg482 hotspot variants compared with other LMNA variants. Inclusion of this cohort in our study was to further interrogate these findings and appreciate the full spectrum of cardiac disease with LMNA variants. While there were no primary outcome events in this subgroup, 4 patients with missense variants affecting the p.Arg482 hotspot did experience advanced heart failure events, highlighting its relevance for overall cardiac outcomes.
Spectrum of Aldosteronism and Cardiovascular Outcomes
https://jamanetwork.com/journals/jamacardiology/fullarticle/2845797
This cohort study investigates the association between spectrum of primary aldosteronism and incident cardiovascular disease in older adults.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2845797
This cohort study investigates the association between spectrum of primary aldosteronism and incident cardiovascular disease in older adults.
Picking Antidepressants—Patient Preferences Beat Biomarkers
https://jamanetwork.com/journals/jama/fullarticle/2845914
Approximately 11% of US adults take an antidepressant medication each year. Only 20% to 25% of people starting an antidepressant reach remission of depression with the first medication selected, and an additional 20% to 25% experience moderate improvement but not remission. The remaining half improve minimally or not at all, leading to treatment changes and often discouragement among patients and treatment discontinuation.
https://jamanetwork.com/journals/jama/fullarticle/2845914
Approximately 11% of US adults take an antidepressant medication each year. Only 20% to 25% of people starting an antidepressant reach remission of depression with the first medication selected, and an additional 20% to 25% experience moderate improvement but not remission. The remaining half improve minimally or not at all, leading to treatment changes and often discouragement among patients and treatment discontinuation.
Using Numerical Comparisons to Help Patients Make Choices
https://jamanetwork.com/journals/jama/fullarticle/2845913
This JAMA Insights explores how using numerical comparisons during patient-clinician encounters can help patients better understand their clinical situation and inform their decision-making.
https://jamanetwork.com/journals/jama/fullarticle/2845913
This JAMA Insights explores how using numerical comparisons during patient-clinician encounters can help patients better understand their clinical situation and inform their decision-making.
Perinatal Depression
https://jamanetwork.com/journals/jama/fullarticle/2845912
To the Editor A recent JAMA Insights provides comprehensive guidance regarding pharmacological treatment of perinatal depression. We wish to remind the medical community that for patients with life-threatening or refractory depression, electroconvulsive therapy (ECT) is a safe and effective treatment in pregnancy. Perinatal depression and its sequelae are among the leading causes of maternal mortality and every intervention, including ECT, should be considered in this population. ECT, one of the most effective therapies for depressive disorders, involves provoking a generalized cerebral seizure under general anesthesia over 6 to 12 treatments.
https://jamanetwork.com/journals/jama/fullarticle/2845912
To the Editor A recent JAMA Insights provides comprehensive guidance regarding pharmacological treatment of perinatal depression. We wish to remind the medical community that for patients with life-threatening or refractory depression, electroconvulsive therapy (ECT) is a safe and effective treatment in pregnancy. Perinatal depression and its sequelae are among the leading causes of maternal mortality and every intervention, including ECT, should be considered in this population. ECT, one of the most effective therapies for depressive disorders, involves provoking a generalized cerebral seizure under general anesthesia over 6 to 12 treatments.
The Hochberg Procedure for the Comparison of Multiple End Points
https://jamanetwork.com/journals/jama/fullarticle/2845970
This Guide to Statistics and Methods provides an overview of the Hochberg procedure, an effective tool for avoiding false-positive conclusions in clinical trials reporting multiple end points.
https://jamanetwork.com/journals/jama/fullarticle/2845970
This Guide to Statistics and Methods provides an overview of the Hochberg procedure, an effective tool for avoiding false-positive conclusions in clinical trials reporting multiple end points.
The Purpose of an Internship
https://jamanetwork.com/journals/jama/fullarticle/2845969
E. E. Irons, M.D., Chicago
https://jamanetwork.com/journals/jama/fullarticle/2845969
E. E. Irons, M.D., Chicago
Rural Health Transformation Program Allocations and Rural Health Needs in the US
https://jamanetwork.com/journals/jama/fullarticle/2845968
This study examines associations between recently released state-level Rural Health Transformation Program funding and measures of rural health, access, and projected reductions in Medicaid spending.
https://jamanetwork.com/journals/jama/fullarticle/2845968
This study examines associations between recently released state-level Rural Health Transformation Program funding and measures of rural health, access, and projected reductions in Medicaid spending.
😱1
Audio Highlights March 6, 2026
https://jamanetwork.com/journals/jama/fullarticle/2846297
Listen to the JAMA Editor’s Summary for an overview and discussion of the important articles appearing in JAMA.
https://jamanetwork.com/journals/jama/fullarticle/2846297
Listen to the JAMA Editor’s Summary for an overview and discussion of the important articles appearing in JAMA.
FDA Approves Menopausal Hormone Therapy Labeling Changes
https://jamanetwork.com/journals/jama/fullarticle/2846272
The US Food and Drug Administration (FDA) approved drug labeling changes for 6 menopausal hormone therapy products to clarify risk considerations.
https://jamanetwork.com/journals/jama/fullarticle/2846272
The US Food and Drug Administration (FDA) approved drug labeling changes for 6 menopausal hormone therapy products to clarify risk considerations.
Most Older Adults Have Rotator Cuff Abnormalities, But Few Show Symptoms
https://jamanetwork.com/journals/jama/fullarticle/2846271
Rotator cuff abnormalities are present in most individuals over 40 years of age, but routine imaging may not identify symptomatic vs asymptomatic shoulders, found a study published in JAMA Internal Medicine.
https://jamanetwork.com/journals/jama/fullarticle/2846271
Rotator cuff abnormalities are present in most individuals over 40 years of age, but routine imaging may not identify symptomatic vs asymptomatic shoulders, found a study published in JAMA Internal Medicine.
Chronic Kidney Disease Severity Linked With Cognitive Impairment Risk
https://jamanetwork.com/journals/jama/fullarticle/2846270
Chronic kidney disease severity was associated with an increased risk of cognitive impairment, according to a prospective study published in JAMA Network Open.
https://jamanetwork.com/journals/jama/fullarticle/2846270
Chronic kidney disease severity was associated with an increased risk of cognitive impairment, according to a prospective study published in JAMA Network Open.
❤1
Are AI Tools Ready to Answer Patients’ Questions?
https://jamanetwork.com/journals/jama/fullarticle/2846269
This Medical News article discusses patient-facing artificial intelligence applications that are in various stages of development.
https://jamanetwork.com/journals/jama/fullarticle/2846269
This Medical News article discusses patient-facing artificial intelligence applications that are in various stages of development.
Error in Figure 1
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2846013
In the Original Investigation titled “Antibiotic De-Escalation in Adults Hospitalized for Community-Onset Sepsis,” published online December 22, 2025, and in the February 2026 issue, there was an error in Figure 1. In the “Excluded because of positive PSA test findings on encounter day 1 or 2” box, the value was updated to 1669. This article was corrected online.
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2846013
In the Original Investigation titled “Antibiotic De-Escalation in Adults Hospitalized for Community-Onset Sepsis,” published online December 22, 2025, and in the February 2026 issue, there was an error in Figure 1. In the “Excluded because of positive PSA test findings on encounter day 1 or 2” box, the value was updated to 1669. This article was corrected online.
Cost-Related Medication Nonadherence Before and After the 2024 Inflation Reduction Act Provisions
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2846012
Health Care Policy
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2846012
Health Care Policy
Important Lessons Learned From Eliminating Race-Based Medicine in Kidney Care
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2846011
As early as the 1960s, the global scientific community recognized race as a purely sociopolitical construct with no consistent definition or biological basis. This recognition was definitively confirmed by an international consortium of thousands of research experts with the Human Genome Project in 2003, which revealed that less than 1% of human DNA correlates with commonly used racial designations. Hence, since the early 2000s it has been widely accepted that race should not be incorporated into practices seeking to define genetic differences to address biomedical concerns.
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2846011
As early as the 1960s, the global scientific community recognized race as a purely sociopolitical construct with no consistent definition or biological basis. This recognition was definitively confirmed by an international consortium of thousands of research experts with the Human Genome Project in 2003, which revealed that less than 1% of human DNA correlates with commonly used racial designations. Hence, since the early 2000s it has been widely accepted that race should not be incorporated into practices seeking to define genetic differences to address biomedical concerns.
Suicidality and Treatment Resistance in Focal Epilepsy
https://jamanetwork.com/journals/jamaneurology/fullarticle/2845901
This cohort study investigates the association between psychiatric disturbance (current or past suicidality, mood, and/or anxiety disorder) at epilepsy diagnosis with the risk of developing future treatment resistance to antiseizure medications.
https://jamanetwork.com/journals/jamaneurology/fullarticle/2845901
This cohort study investigates the association between psychiatric disturbance (current or past suicidality, mood, and/or anxiety disorder) at epilepsy diagnosis with the risk of developing future treatment resistance to antiseizure medications.
👌1
Epstein-Barr Virus Antibodies and Multiple Sclerosis
https://jamanetwork.com/journals/jamaneurology/fullarticle/2845900
This case-control study investigates if Epstein-Barr virus antibodies can be used to distinguish multiple sclerosis from myelin oligodendrocyte glycoprotein antibody–associated disease and neuromyelitis optica spectrum disorder.
https://jamanetwork.com/journals/jamaneurology/fullarticle/2845900
This case-control study investigates if Epstein-Barr virus antibodies can be used to distinguish multiple sclerosis from myelin oligodendrocyte glycoprotein antibody–associated disease and neuromyelitis optica spectrum disorder.
🔥1
FDA’s Regulatory Reforms to Unlock Competition and Lower Drug Costs
https://jamanetwork.com/journals/jama/fullarticle/2846432
This Viewpoint from the FDA explains efforts to remove burdensome criteria for biosimilar approvals and encourage use of biosimilars over branded biologics, which could lead to greater access to biosimilars for patients and reduce treatment costs.
https://jamanetwork.com/journals/jama/fullarticle/2846432
This Viewpoint from the FDA explains efforts to remove burdensome criteria for biosimilar approvals and encourage use of biosimilars over branded biologics, which could lead to greater access to biosimilars for patients and reduce treatment costs.